GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Inogen Inc (NAS:INGN) » Definitions » Cash Ratio

Inogen (Inogen) Cash Ratio

: 1.77 (As of Dec. 2023)
View and export this data going back to 2014. Start your Free Trial

The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. Inogen's Cash Ratio for the quarter that ended in Dec. 2023 was 1.77.

Inogen has a Cash Ratio of 1.77. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.

The historical rank and industry rank for Inogen's Cash Ratio or its related term are showing as below:

INGN' s Cash Ratio Range Over the Past 10 Years
Min: 1.77   Med: 4.04   Max: 5.16
Current: 1.77

During the past 13 years, Inogen's highest Cash Ratio was 5.16. The lowest was 1.77. And the median was 4.04.

INGN's Cash Ratio is ranked better than
60.33% of 857 companies
in the Medical Devices & Instruments industry
Industry Median: 1.25 vs INGN: 1.77

Inogen Cash Ratio Historical Data

The historical data trend for Inogen's Cash Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Inogen Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Ratio
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.17 4.08 3.99 2.86 1.77

Inogen Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash Ratio Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.86 2.75 2.87 2.29 1.77

Competitive Comparison

For the Medical Devices subindustry, Inogen's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Inogen Cash Ratio Distribution

For the Medical Devices & Instruments industry and Healthcare sector, Inogen's Cash Ratio distribution charts can be found below:

* The bar in red indicates where Inogen's Cash Ratio falls into.



Inogen Cash Ratio Calculation

The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.

Inogen's Cash Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash Ratio (A: Dec. 2023 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=128.471/72.496
=1.77

Inogen's Cash Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash Ratio (Q: Dec. 2023 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=128.471/72.496
=1.77

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Inogen  (NAS:INGN) Cash Ratio Explanation

The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.

The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.

In general, the higher the cash ratio, the better the company's liquidity position.


Inogen Cash Ratio Related Terms

Thank you for viewing the detailed overview of Inogen's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Inogen (Inogen) Business Description

Traded in Other Exchanges
Address
301 Coromar Drive, Goleta, CA, USA, 93117
Inogen Inc is a medical technology company that develops and manufactures portable oxygen concentrators used to deliver oxygen therapy to patients with chronic respiratory conditions. Its key product, the Inogen One system, is a lightweight alternative to traditional, stationary oxygen concentrator systems and oxygen tanks. The firm sells its products to home medical equipment providers and also rents products directly to patients. Internationally, Inogen sells its products through distributors or large gas companies and home oxygen providers. Inogen generates the majority of its revenue in the United States.
Executives
Thomas A. West director C/O INTERSECT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Stanislav Glezer officer: EVP, Chief Medical Officer C/O INOGEN, INC., 326 BOLLAY DRIVE., GOLETA CA 93117
Jason Somer officer: EVP, Gen. Counsel & Secretary C/O INOGEN, INC., 301 COROMAR DRIVE, GOLETA CA 93117
Glenn S Boehnlein director 2825 AIRVIEW BLVD, KALAMAZOO MI 49002
Mary Kay Ladone director 130 EAST RANDOLPH STREET, SUITE 1000, CHICAGO IL 60601
Kevin M King director C/O AFFYMETRIX, INC., 3420 CENTRAL EXPRESSWAY, SANTA CLARA CA 95051
Kristin A. Caltrider officer: EVP, CFO and Treasurer C/O INOGEN, INC., 301 COROMAR DRIVE, GOLETA CA 93117
Anderson Ray Benjamin M director 1100 NORTH WASHINGTON STREET, DELPHI IN 46923
Michael K. Sergesketter officer: EVP, CFO and Treasurer 301 COROMAR DRIVE, GOLETA CA 93117
Raymond Huggenberger director, officer: See Remarks 326 BOLLAY DRIVE, GOLETA CA 93117
Alison Bauerlein officer: See Remarks 326 BOLLAY DRIVE, GOLETA CA 93117
Brenton Taylor officer: Vice President, Engineering 326 BOLLAY DRIVE, GOLETA CA 93117
Elizabeth Mora director C/O MKS INSTRUMENTS, INC., 2 TECH DRIVE, SUITE 201, ANDOVER MA 01810
George J Parr director BECTON, DICKINSON AND COMPANY, 1 BECTON DRIVE, FRANKLIN LAKES NJ 07417
Byron Myers officer: Vice President, Marketing 326 BOLLAY DRIVE, GOLETA CA 93117

Inogen (Inogen) Headlines

From GuruFocus

Inogen to Present at 43rd Annual William Blair Growth Stock Conference

By Business Wire Business Wire 05-15-2023

Inogen Announces Board of Director Changes

By Business Wire Business Wire 03-23-2022

Inogen Completes Acquisition of Physio-Assist

By Business Wire 09-18-2023

Inogen Names Kristin Caltrider as Chief Financial Officer

By Business Wire Business Wire 03-04-2022

Inogen Announces CFO Transition Plan

By Business Wire 09-07-2023